AzTrials
AzTrials

Alcoholic HepatitisNCT03157388

The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis.

A study testing Combined Vancomycin and Gentamycin and Meropenem in people with Alcoholic Hepatitis, run by University of Aarhus at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Alcoholic hepatitis (AH) is a severe alcohol induced hepatic inflammation that leads to jaundice and liver failure. Gut derived bacterial translocation to the liver is currently thought to be one of the main inflammatory drivers of the disease. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Alcoholic Hepatitis
What is being tested?
Combined Vancomycin and Gentamycin and Meropenem
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
15 participants
Where
1 siteDenmark
Study dates
1 Jun 2017to 1 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • A first time diagnose of AH by a combination of physical and laboratory criteria:
  • A history of excessive alcohol ingestion (10 units or more per day) until at least three weeks before admission
  • Acute jaundice (developed over at most 2 weeks, serum bilirubin > 80 μmol/l).
  • liverbiopsy will be performed in case of doubt regarding the diagnosis.

Who cannot join

  • Non-native speaking Danish
  • Viral hepatitis,
  • Autoimmune liver disease,
  • Bile duct obstruction,
  • Liver tumours or any other cancer,
  • Presence of an infectious focus (either clinically assessed or based on chest x-ray, urine samples or ascites puncture),
Show all 10Show fewer
  • On-going gastrointestinal bleeding or bleeding within the previous three months
  • Any prior immune-modulating therapy.
  • Any known gastrointestinal disease
  • Contraindications against/allergy towards the used antibiotics

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Aarhus University Hospital

    Aarhus, 8000

Other trials in Denmark

About this study

Alcoholic hepatitis (AH) is a severe alcohol induced hepatic inflammation that leads to jaundice and liver failure. Gut derived bacterial translocation to the liver is currently thought to be one of the main inflammatory drivers of the disease.

This project investigates the effects of gut sterilisation with broad spectrum antibiotics in patients with AH

Read the detailed description

Alcoholic hepatitis (AH) is a severe alcohol induced hepatic inflammation that leads to jaundice and liver failure. The incidence of AH is increasing and the disease is associated with a high mortality. In spite of numerous clinical trials both treatment and prognosis have remained essentially unchanged for decades, emphasizing the need to improve our understanding of the disease mechanisms behind AH.

The current perception of the pathogenesis of alcohol-induced liver injury mainly derives from animal models, and the resident hepatic macrophages, the Kupffer cells, seem to play an important role. Activation of these cells may give rise to most of the hallmark clinical findings of AH: The cytokines released initiate hepatic inflammation and an acute phase response, recruit neutrophils, and activate stellate cells, contributing to the acute portal hypertension. Jaundice is due to intrahepatic cholestasis caused by down regulation of the bilirubin transporters on the basolateral hepatocyte membrane. Hepatic macrophages are thought to be activated by the bacterial derived endotoxins/lipopolysaccharides (LPS) present in the portal blood because of an alcohol-induced increase in gut-blood permeability with translocation of bacteria, as found in patients with alcoholic liver injury. LPS is recognized by the hepatic macrophages via a membrane complex including the pathogen recognition receptor molecule Toll-like receptor 4 (TLR-4). LPS Binding Proteins (LBP) produced by hepatocytes then bind and present LPS to the membrane glycoprotein CD14 that in turn activates TLR-4. In support of these mechanisms, alcohol-induced liver injury is reduced in knockout mice missing LBP, CD14, and TLR-4. Likewise, chemical destruction of hepatic macrophages in rats prevents alcohol-induced liver injury, as does cleansing the gut flora with antibiotics.

Human hepatic macrophages when activated, express their surface receptor CD163. We and others have previously shown that sCD163 is released from the liver in alcoholic liver disease, that its plasma concentration predicts mortality in patients with acute liver failure and is as a marker of portal hypertension and a predictor of clinical decompensation in patients with liver cirrhosis. Very recently we have directly demonstrated hepatic macrophage activation in human AH paralleling the disease severity, and to suggest this to be elicited by LPS.

The line of evidence presented above provides rationale for testing whether intervention toward bacterial translocation may result in a diminished immune response in human AH. Consequently, in this study the investigators seek to perform total gut microbiota eradication by combining 3 different orally administered antibiotics. The investigators have chosen antibiotics that are not absorbed into the systemic circulation, because the investigators want to limit the effects to the gastrointestinal tract.

Being tested
Combined Vancomycin and Gentamycin and Meropenem
Keywords
inflammation, Macrophages, CD163
Medical subject headings
Hepatitis, Alcoholic, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Combined Vancomycin and Gentamycin and MeropenemDrug

    The following combined antibiotic regime will be administered for eradication of gut bacteria.

    7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin "Hospira"), powder for concentrate and gentamycin 40 mg ("Hexamycin®"), solution and meropenem 500 mg (Meropenem "Hospira"), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice.

Study groups in NCT03157388
Study groupRoleWhat they receive
InterventionExperimentalCombined Vancomycin and Gentamycin and Meropenem
Receives: Drug: Combined Vancomycin and Gentamycin and Meropenem

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Macrophage activation cd163

    Difference in serum levels of macrophage activation markers sCD163

    Measured: 1 year

Secondary outcomes (3)
  1. LBP

    serum levels of Lipopolysaccaride binding protein

    Measured: 1 year

  2. TNF alfa

    serum levels of, Tumor Necrosis Factor-alfa

    Measured: 1 year

  3. Interleukin-1b

    serum levels of, Interleukin-1b

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2017
  2. Study start1 Jun 2017
  3. Primary completion1 Jun 2018
  4. Study completion1 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Model description
15 patients with alcoholic hepatitis will be consecutively included and compared to a historical cohort of AH patients
Masking
None (open label)
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03157388
Sponsor's protocol ID
1-10-72-1-15
Status last verified
Dec 2018
First submitted
15 May 2017
Last updated
23 May 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Combined Vancomycin and Gentamycin and Meropenem in people with Alcoholic Hepatitis, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 May 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Macrophage activation cd163 (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 May 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in